CVD screening in low-risk, asymptomatic adults: clinical trials needed
Related Experiment Video
Updated: May 19, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Tamar S Polonsky1, Philip Greenland
1University of Chicago Medical Center, Department of Medicine, Section of Cardiology, 5841 South Maryland Avenue, MC 6080, Chicago, IL 60637, USA.
Insights
Novel risk markers can identify asymptomatic individuals for cardiovascular disease (CVD) primary prevention. Clinical trials are needed to confirm their effectiveness and cost-efficiency in guiding statin therapy.
Area of Science:
- Cardiology
- Preventive Medicine
- Biomarker Research
Background:
- Cardiovascular disease (CVD) poses a significant public health challenge, with many events occurring in asymptomatic individuals lacking high-risk profiles.
- Current risk assessment tools may not adequately identify all individuals who could benefit from primary prevention strategies.
Approach:
- Investigating novel risk markers like carotid intima-media thickness, C-reactive protein, coronary artery calcium scores, and genetic risk scores.
- Evaluating the potential of these markers to identify asymptomatic, low-risk populations for intensive risk-factor modification.
Key Points:
- Novel markers may improve the identification of candidates for primary CVD prevention.
- Uncertainty remains regarding their utility in guiding statin therapy, influencing medication adherence, and cost-effectiveness.
- Asymptomatic, low-risk populations require further clinical trials to assess these novel tests.
Conclusions:
- Clinical trials are essential to validate the role of novel risk markers in primary CVD prevention.
- Integrating novel markers with traditional risk factor monitoring is crucial for optimizing preventive strategies.
- Further research is needed to determine the cost-effectiveness and impact on patient adherence for these emerging diagnostic tools.
Abstract:
The public-health impact of cardiovascular disease (CVD) remains high despite advances in prevention and treatment. Large numbers of cardiovascular events occur in asymptomatic people who do not have a high level of risk from single risk factors or in terms of multivariable risk scores. Novel risk markers, such as carotid intima-media thickness, high-sensitivity measurement of C-reactive protein, coronary artery calcium score, and genetic risk scores have been suggested as new ways to identify candidates for primary prevention of CVD through intensive risk-factor modification. Yet, many questions remain unanswered. Can these novel markers be used to identify adults who will benefit from statin therapy? How will novel markers affect medication adherence? Is screening using these markers cost-effective? Our opinion is that clinical trials of one or more of these novel tests, combined with monitoring of traditional risk factors, are needed in asymptomatic, low-risk populations.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease IV: Preventive Measures
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies
Hypertension III: Clinical Manifestations and Diagnostic Studies
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
